Early detection of cancer: Molecular screening

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 335-347

  Hennessy, Bryan ^a   Bast, Robert C ^a   Gonzalez Angulo, Ana Maria ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82955186595     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10025-1     Document Type: Chapter

References (83)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652.
2. Barrett-Connor EL, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125.
3. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999, 91:1829. (See comment)(erratum appears in J Natl Cancer Inst.
4. Ozanne EM, Klemp JR, Esserman LJ Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J 2006, 12:103.
5. Amling CL Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening?. Curr Treat Options Oncol 2006, 7:337.
6. Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002, 20:2701.
7. Calderon-Margalit R, Paltiel O Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004, 112:357.
8. Anglian Breast Cancer Study Group. Br J Cancer 2000, 83:1301. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases.
9. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676.
10. Easton DF, Ford D, Bishop DT Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265.
11. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379.
12. Dapic V, Carvalho MA, Monteiro ANA Breast cancer susceptibility and the DNA damage response. Cancer Control 2005, 12:127.
13. Thompson D, Easton D The genetic epidemiology of breast cancer genes. J Mam Gland Biol Neopl 2004, 9:221.
14. Johnson N, Fletcher O, Naceur-Lombardelli C, et al. Interaction between CHEK2 1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005, 366:1554.
15. Telang NT, Li G, Katdare M Prevention of early-onset familial/hereditary colon cancer: new models and mechanistic biomarkers (review). Int J Oncol 2006, 28:1523.
16. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993, 329:1977.
17. Liebermann D Screening for colorectal cancer in average-risk populations. Am J Med 2006, 119:728.
18. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784.
19. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006, 54:177-184.
20. Houssami N, Cuzick J, Dixon JM The prevention, detection, and management of breast cancer. Med J Australia 2006, 184:230.
21. Kuhl CK, Kuhn W, Schild H Management of women at high risk for breast cancer: new imaging beyond mammography. Breast 2005, 14:480.
22. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873.
23. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159.
24. Rebbeck TR Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002, 38(Suppl 6):S15.
25. Balmana J, Sanz J, Bonfill X, et al. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 2004, 112:647.
26. Paradiso A, Muggia F Familial breast cancer screening: ethical and social implications. Ann Oncol 2004, 15(Suppl 1):I5-I6.
27. Moller P Costs and benefits of diagnosing familial breast cancer. Ann Oncol 2004, 15(Suppl 1):I55-I59.
28. Cipollini G, Tommasi S, Paradiso A, et al. Genetic alterations in hereditary breast cancer. Ann Oncol 2004, 15(Suppl 1):I7-I13.
29. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673.
30. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422.
31. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005, 102:8315.
32. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362.
33. Wang Y, Klijn JGM, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671.
34. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284.
35. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353.
36. Callagy G, Pharoah P, Chin S-F, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005, 205:388.
37. Rhodes DR, Chinnaiyan AM Integrative analysis of the cancer transcriptome. Nat Genet 2005, 37(Suppl):S31.
38. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101:9309.
39. Buckhaults P, Zhang Z, Chen Y-C, et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003, 63:4144.
40. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteom 2005, 4:346.
41. Kammerer U, Thanner F, Kapp M, et al. Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res 2003, 23:1051.
42. Ellis NA, Kirchhoff T, Mitra N, et al. Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genet Epidemiol 2006, 30:48.
43. Gasco M, Argusti A, Bonanni B, Decensi A SERMs in chemoprevention of breast cancer. Eur J Cancer 2005, 41:1980.
44. Arvanitis DA, Papadakis E, Zafiropoulos A, Spandidos DA Fractional allele loss is a valuable marker for human lung cancer detection in sputum. Lung Cancer 2003, 40:55.
45. Halling KC, Rickman OB, Kipp BR, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 2006, 130:694.
46. Levin B Molecular screening testing for colorectal cancer. Clin Cancer Res 2006, 12:5014.
47. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351:2704.
48. Mendrinos S, Nolen JDL, Styblo T, et al. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer 2005, 105:178.
49. Hudelist G, Singer CF, Pischinger KID, et al. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 2006, 6:1989.
50. Junker K, Fritsch T, Hartmann A, et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006, 114:279.
51. Dirix L, Van Dam P, Vermeulen P Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?. Curr Opin Oncol 2005, 17:551.
52. Seregni E, Coli A, Mazzucca N Italian Group Ria-Irma Test IAoNM. Circulating tumour markers in breast cancer. Eur J Nucl Med Molec Imag 2004, 31(Suppl 1):S15.
53. Duffy MJ Serum tumor markers in breast cancer: are they of clinical value. Clin Chem 2006, 52:345.
54. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589.
55. Araki M, Nieder AM, Manoharan M, et al. Lack of progress in early diagnosis of bladder cancer. Urology 2007, 69:270.
56. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer, (See comment.). N Engl J Med 2004, 351:781.
57. Reinholz MM, Nibbe A, Jonart LM, et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 2005, 11:3722.
58. Swisher EM, Wollan M, Mahtani SM, et al. Specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 2005, 193:662.
59. Masuda T-A, Kataoka A, Ohno S, et al. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol 2005, 26:721.
60. Stathopoulos EN, Sanidas E, Kafousi M, et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005, 16:240.
61. Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11:3678.
62. Becker FF, Wang XB, Huang Y, et al. Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A 1995, 92:860.
63. Ding C, Chiu RWK, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci U S A 2004, 101:10762-10767.
64. Sheen-Chen S-M, Liu Y-W, Eng H-L, Chou F-F Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidem Biomark Preven 2005, 14:715.
65. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006, 94:524.
66. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531.
67. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568.
68. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793.
69. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817.
70. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530.
71. Jeffrey SS, Lonning PE, Hillner BE Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Comp Cancer Net 2005, 3:291.
72. Espinosa E, Redondo A, Vara JAF, et al. High-throughput techniques in breast cancer: a clinical perspective. Eur J Cancer 2006, 42:598.
73. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Path 2004, 164:35.
74. Paik S, Kim C-y, Song Y-k, Kim W-S Technology insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nature Clin Prac Oncol 2005, 2:246.
75. Segal E, Friedman N, Kaminski N, Regev A, Koller D From signatures to models: understanding cancer using microarrays. Nat Genetics 2005, ;37(Suppl):S38.
76. Hayes DF Prognostic and predictive factors revisited. Breast 2005, 14:493.
77. Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R Perspective: a program to improve protein biomarker discovery for cancer. J Prot Res 2005, 4:1104.
78. Almeida JS, Chen C, Gorlitsky R, et al. Data integration gets 'sloppy'. Nat Biotechnol 2006, 24:1070.
79. Liu H, Li J, Wong L Selection of patient samples and genes for outcome prediction. Proc IEEE Comput Syst Bioinform Conf 2004, 382.
80. Shen L, Tan EC Dimension reduction-based penalized logistic regression for cancer classification using microarray data. IEEE/ACM Trans Comput Biol Bioinform 2005, 2:166.
81. MacDonald JW, Ghosh D COPA: cancer outlier profile analysis. Bioinform 2006, 22:2950.
82. Zhou X, Wang X, Dougherty ER Multi-class cancer classification using multinomial probit regression with Bayesian gene selection. Syst Biol (Stevenage) 2006, 153:70.
83. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E Cancer biomarkers: a systems approach. Nat Biotechnol 2006, 24:905.